|
|
 |
|
Viewing report
|
|
|
|
Antihypertensives - Two Years to Shape the Market?
Datamonitor, Dec 2005, Pages: 200
We expect the antihypertensive market to exceed $50bn by 2014 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to be savvy regarding marketing and pricing structures for their products, as only the most cunning and aggressive companies look set to survive.
Scope of this title:
- Event-driven sales forecasts, for the period 2005-14, for the US, Japan, France, Germany, Italy, Spain and the UK, along with a global overview
- Discussion of individual products in four main classes; beta blockers (BBs), CCBs, ACE inhibitors and the ARBs
- Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches
- Commercial impact case studies on R&D innovation, clinical trial data and European healthcare reform
Highlights
The ARBs are now the most prescribed class of antihypertensives, as aggressive marketing and premium-pricing enables manufacturers to deliver strong growth in a highly genericized market. Post-2009, however, the value of the ARB class is set to flatten on the back of generic erosion and indication expansion for the ARBs as a class.
In order for companies to achieve and maintain growth in this sector, companies need to be savvy regarding the impact of healthcare reform across the globe, particularly in Europe, with marketers who are charged with selling drugs across the EU needing to challenge the attitude that Europe is one, uniform, market like the US and Japan.
Novartis SPP100 (aliskiren) looks set to become the first innovative treatment for hypertension in over a decade. However, due to concerns regarding premium-pricing and similar efficacy compared to the ARBs, market penetration is expected to be slow in the short-term until strong cardiovascular outcome data for the class becomes available.
Reasons to order your copy:
- Access independent, event-driven forecasts for key antihypertensive products and classes across the seven major markets
- Assess the potential impact of clinical trial results, EU healthcare reform and new product launches on the antihypertensive market
- Gain insight into the antihypertensive market via up-to-date thought-leader opinions and gold-standard IMS Health sales data
Customers who bought this item also bought
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
Renin Inhibitors: A Novel Approach to Hypertension
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Commercial Insight: Antihypertensives - New Challenges for a Maturing Market
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Handbook of Hypertension
Antihypertensives - Weak Pipeline Leaves Innovation to Novartis
Commercial Insight: Cardiovascular Market Overview - Raft of Patent Expires Threaten Blockbusters
Commercial Insight: Antihypertensives - Can Manufacturers Maintain Value?
Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market
|
|
|
|
